Vivavision Biotech Announces First Patient Dosed in Phase II Clinical Trial of VVN1901 Ophthalmic Solution for Neurotrophic Keratitis in China

This clinical study is "An adaptive, randomized, double-blind, vehicle-controlled, multicenter Phase II clinical study evaluating the efficacy and safety of VVN1901 eye drops in patients with moderate or severe neurotrophic keratitis." Professor Yuan Jin from Beijing Tongren Hospital, Capital Medical University, serves as the Principal Investigator (PI) of the leading unit.

Previously, VVN1901 eye drops had completed Phase I clinical research. The study results showed that single and multiple administrations of 10µg/ml, 20µg/ml, and 40µg/ml VVN1901 eye drops in healthy adult subjects in China resulted in almost no systemic exposure, demonstrating good safety and tolerability without unexpected safety issues.

Current treatment methods have not fundamentally solved the problem of corneal nerve damage, seriously affecting patients' health and quality of life. According to the expert consensus on NK diagnosis and treatment, nerve growth factor eye drops are considered one of the more promising treatments, representing a new approach. If VVN1901 eye drops are successfully launched, they will provide a new treatment option for NK patients and healthcare providers.

In the future, VIVAVISION will continue to strive for providing more comprehensive treatment solutions for ophthalmic diseases, steadily advancing its multi-pipeline and multi-series clinical research plans. It aims to offer patients and doctors more and better choices, benefiting more patients with eye conditions, and making every effort to help patients achieve bright eyes and a wonderful life!

VVN1901 is a recombinant human nerve growth factor eye drop independently developed by VIVAVISION, with an indication for neurotrophic keratitis. Recombinant human nerve growth factor is a protein that nourishes neuronal cell bodies and promotes the growth of neuronal axons. It functions through the specific high-affinity receptor (tyrosine kinase receptor type I, also known as TrkA) and the non-specific low-affinity receptor (p75NTR) neurotrophic signaling pathways, playing a role in maintaining and differentiating neurons. It can effectively promote the repair and regeneration of corneal nerves.

VIVAVISION is a clinical-stage innovative pharmaceutical company focused on the field of ophthalmic treatments. The company was founded by a team of world-class experts in ophthalmic drug research and development and has established a unique platform for developing innovative ophthalmic drugs. Several of its self-developed innovative drug products have entered or are about to enter the clinical stage.

For more information, please visit: www.vivavisionbio.com

Disclaimer

The information related to the incubated companies is provided by the incubated companies and has not been independently verified by our company. In any case, our company will not be responsible for any direct or indirect losses or damages (whether due to tort, contractual liability, or otherwise) caused by inaccurate or omitted information in this press release or the use of the information contained herein.